Ultragenyx Pharmaceutical shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral rating and lowered the price target from $61 to $25.

Benzinga Newsdesk www.benzinga.com Negative 97.1%

Neg 97.1% Neu 0% Pos 0%

Comments

No comments yet. Be the first!